1. Home
  2. IDE vs HELP Comparison

IDE vs HELP Comparison

Compare IDE & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.41

Market Cap

203.7M

Sector

Finance

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$7.54

Market Cap

233.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDE
HELP
Founded
2010
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.7M
233.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDE
HELP
Price
$13.41
$7.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$51.50
AVG Volume (30 Days)
29.1K
2.0M
Earning Date
01-01-0001
07-01-2026
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.36
$3.76
52 Week High
$14.30
$8.55

Technical Indicators

Market Signals
Indicator
IDE
HELP
Relative Strength Index (RSI) 42.59 62.04
Support Level $13.27 $4.18
Resistance Level $13.95 $8.55
Average True Range (ATR) 0.24 0.54
MACD -0.02 0.05
Stochastic Oscillator 39.02 59.70

Price Performance

Historical Comparison
IDE
HELP

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: